Advertisement

Zusammenfassung

Memantin wurde ab Anfang der 80er Jahre zunächst in der Behandlung der Spastik (Grossmann und Schütz 1982, Sontag et al. 1982, Mundinger und Milios 1985) und in der symptomatischen Therapie bei cerebralem Koma (Miltner 1982) verwendet. Ab Anfang der 90er Jahre wurde Memantin in der Behandlung dementieller Erkrankungen eingesetzt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anonymous (1996) Hirnleistungsstörungen (Demenz). Wissenschaftliche Informationen. Akatinol Memantin. Merz Pharma, Frankfurt/MGoogle Scholar
  2. Allen HL, Iversen LL (1990) Phencyclidine, dizocilpine, and cerebrocortical neurons. Science 247: 221PubMedCrossRefGoogle Scholar
  3. Ambrozi L, Danielczyk W (1988) Die Behandlung zerebraler Funktionsstörungen mit Memantine bei psychogeriatrischen Patienten — Ergebnisse einer Phase-II-Doppelblind-Studie. Pharmacopsychiatry 21: 144–146PubMedCrossRefGoogle Scholar
  4. Andaloro VJ, Monaghan DT, Rosenquist TH (1998) Dextromethorphan and other N-methyl-D-aspartate receptor antagonists are teratogenic in the avian embryo model. Pediatr Res 43: 1–7PubMedCrossRefGoogle Scholar
  5. Andreassen OA, Aamo TO, Jorgensen HA (1996) Inhibition by memantine of the development of persistent oral dyskinesias induced by longterm haloperidol treatment of rats. Br J Pharmacol 119: 751–757PubMedCrossRefGoogle Scholar
  6. Arendash GW, Millard WJ, Dunn AJ, Meyer EW (1987) Long-term neuropathological and neurochemical effects of nucleus basalis lesions in the rat. Science 238: 952–956PubMedCrossRefGoogle Scholar
  7. Barnes CA, Danysz W, Parsons CG (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8: 565–571PubMedCrossRefGoogle Scholar
  8. Behl C, Rupprecht R, Skutella T, Holsboer F (1995) Haloperidol-induced cell death — mechanism and protection with vitamin E in vitro. NeuroReport 7: 360–364PubMedGoogle Scholar
  9. Blanpied TA, Boeckman FA, Aizenman E, Johnson JW (1997) Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 77: 309–323PubMedGoogle Scholar
  10. Bliss TVP, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31–39PubMedCrossRefGoogle Scholar
  11. Bouvier M, Szatkowski M, Amato A, Attwell D (1992) The glial cell glutamate uptake carrier countertransports pH-changing anions. Nature 360: 471–474PubMedCrossRefGoogle Scholar
  12. Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12: 4427–4436PubMedGoogle Scholar
  13. Clements JD, Lester RAJ, Tong G, Jahr CE, Westbrook GL (1992) The time course of glutamate in the synaptic cleft. Science 258: 1498–1501PubMedCrossRefGoogle Scholar
  14. Corbett D (1989) Possible abuse potential of the NMDA antagonist MK-801. Behav Brain Res 34: 239–246PubMedCrossRefGoogle Scholar
  15. Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G (1994) Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? — Case of amantadine and memantine. J Neural Transm [PD-Sect] 7:155–166CrossRefGoogle Scholar
  16. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies. Neurosci Biobehav Rev 21: 455–468PubMedCrossRefGoogle Scholar
  17. De Boni U, Mclachlan DRC (1985) Controlled induction of paired helical filaments of the Alzheimer type in cultured human neurons, by glutamate and aspartate. J Neurol Sci 68: 105–118PubMedCrossRefGoogle Scholar
  18. Dimpfel W (1995) Effect of memantine on synaptic transmission in the hippocampus in vitro. Arzneimittelforschung/Drug Res 45: 1–5Google Scholar
  19. Ditzler K (1991) Efficacy and tolerability of memantine in patients with dementia syndrome. Arzneimittelforschung/Drug Res 41: 773–780Google Scholar
  20. Dunn JP, Henkel JG, Gianutsos G (1986) Pharmacological activity of amantadine: effect of N-alkyl substitution. J Pharm Pharmacol 38: 353–356PubMedCrossRefGoogle Scholar
  21. Erdö SL, Schäfer M (1991) Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. Eur J Pharmacol 198: 215–217PubMedCrossRefGoogle Scholar
  22. Fleischhacker WW, Buchgeher A, Schubert H (1986) Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry 10: 87–93PubMedCrossRefGoogle Scholar
  23. Frankiewicz T, Potier B, Bashir ZI, Collingridge GL, Parsons CG (1996) Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampus slices. Br J Pharmacol 117: 689–697PubMedCrossRefGoogle Scholar
  24. Freudenthaler S, Schreeb KH, Bookye E, Gundert-Remy U, Gleiter CH (1997) Influence of urinary pH and urine flow on renal excretion of memantine. Eur J Clin Pharmacol 52: A11Google Scholar
  25. Görtelmeyer R, Erbler H (1992) Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung/Drug Res 42: 904–913Google Scholar
  26. Görtelmeyer R, Pantev M, Parsons CG, Quack G (1993) Die Behandlung des dementiellen Syndroms mit Akatinol Memantine, einem Modulator des glutamatergen Systems — präklinische und klinische Ergebnisse. In: Von Wild K (Hrsg) Spektrum der Neurorehabilitation. Zuckerschwerdt, München Bern Wien New York, S 3–10Google Scholar
  27. Groh D, Rodewald S, Rammsayer T (1996) Experimentelle Studie zum Einfluß des NMDA-Rezeptorenantagonisten Memantine auf Lern-und Gedächtnisfunktionen bei gesunden Probanden. Fortschr Neurol Psychiatr 64: 144Google Scholar
  28. Grossmann W, Schütz W (1982) Memantin und neurogene Blasenstörungen im Rahmen spastischer Zustandsbilder. Arzneimittelforschung/Drug Res 32: 1273–1276Google Scholar
  29. Heim C, Sontag K-H (1995) Memantine prevents progressive functional neurodegeneration in rats. J Neural Transm [Suppl] 46: 117–130Google Scholar
  30. Henkel JG, Hane JT (1982) Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution. J Med Chem 25: 51–56PubMedCrossRefGoogle Scholar
  31. Hölter SM, Danysz W, Spanagel R (1996) Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol 314: R1–R2PubMedCrossRefGoogle Scholar
  32. Jackisch R, Link T, Neufang B, Koch R (1992) Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 320: 21–42PubMedGoogle Scholar
  33. Janiec W, Piekarska T, Szczypior M, Misterkiewicz E (1977) The effect of apomorphine, amantadine and dimethylaminoadamantane on the level of cyclic AMP in the rat striatum. Pol J Pharmacol Pharm 29: 93–99PubMedGoogle Scholar
  34. Karobath ME (1974) Amantadine and D-145, an amantadine derivative, do not effect dopamine sensitive adenylate cyclase from the caudate-putamen of the rat brain. Eur J Pharmacol 28: 376–378PubMedCrossRefGoogle Scholar
  35. Keilhoff G, Wolf G (1992) Memantine prevents quinolinic acid-induced hippocampal damage. Eur J Pharmacol 219: 451–454PubMedCrossRefGoogle Scholar
  36. Koh J-Y, Yang LL, Cotman CW (1990) β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533: 315–320PubMedCrossRefGoogle Scholar
  37. Kornhuber J, Streifler M (1992) Adamantanamine. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd 5. Springer, & Wien New York, S 59–76Google Scholar
  38. Kornhuber J, Quack G (1995) Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195: 137–139PubMedCrossRefGoogle Scholar
  39. Kornhuber J, Weller M (1997) Psychotogenicity and NMDA receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41: 135–144PubMedCrossRefGoogle Scholar
  40. Kornhuber J, Bormann J, Retz W, Hübers M, Riederer P (1989a) Memantine displaces [3H] MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589–590PubMedCrossRefGoogle Scholar
  41. Kornhuber J, Mack-Burkhardt F, Riederer P (1989b) Regional distribution of [3H]MK-801 binding sites in the human brain. Brain Res 489: 397–399PubMedCrossRefGoogle Scholar
  42. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (1991) Effects of the 1-amino-ada-mantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol Mol Pharmacol Sect 206: 297–300CrossRefGoogle Scholar
  43. Kornhuber J, Schoppmeyer K, Riederer P (1993) Affinity of 1-aminoadamantanes for the σ binding site in post-mortem human frontal cortex. Neurosci Lett 163: 129–131PubMedCrossRefGoogle Scholar
  44. Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm [Suppl] 43: 91–104Google Scholar
  45. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P (1995) Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34: 713–721PubMedCrossRefGoogle Scholar
  46. Kornhuber J, Retz W, Sitzmann L, Schmidtke A, Herbert MK (1996) The NMDA-receptor antagonist memantine is not psychotomimetic in young healthy volunteers. Soc Neurosci Abstr 22: 178Google Scholar
  47. Kornhuber J, Jellinger K, Wiltfang J, Leblhuber F, Riederer P (1999) The N-methyl-D-aspartate receptor channel blocker amantadine does not cause histological alterations in human brain tissue. Acta Neuropathol (im Druck)Google Scholar
  48. Kroemer RT, Koutsilieri E, Hecht P, Liedl KR, Riederer P, Kornhuber J (1998) Quantitative analysis of the structural requirements for blockade of the NMDA receptor at the PCP binding site. J Med Chem 41: 393–400PubMedCrossRefGoogle Scholar
  49. Lampe H, Bigalke H (1991) Modulation of glycineactivated membrane current by adamantane derivatives. NeuroReport 2: 373–376PubMedCrossRefGoogle Scholar
  50. Lipton SA (1992) Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology 42: 1403–1405PubMedCrossRefGoogle Scholar
  51. Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med 330: 613–622PubMedCrossRefGoogle Scholar
  52. Lupp A, Lücking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263: 717–724PubMedGoogle Scholar
  53. Maj J (1982) Die Wirkung von Memantin auf zentrale Neurotransmittersysteme. Arzneimittelforschung/Drug Res 32: 1256–1259Google Scholar
  54. Marcea JT, Tempel D (1988) Wirkung von Memantin versus dh-Ergotoxin beim hirnorganischen Psychosyndrom. Therapiewoche 38: 3097–3100Google Scholar
  55. Marquis KL, Moreton JE (1987) Animal models of intravenous phencyclinoid self-administration. Pharmacol Biochem Behav 27: 385–389PubMedCrossRefGoogle Scholar
  56. Masuo K, Enomoto K, Maeno T (1986) Effects of memantine on the frog neuromuscular junction. Eur J Pharmacol 130: 187–195PubMedCrossRefGoogle Scholar
  57. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992) β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excito-toxicity. J Neurosci 12: 376–389PubMedGoogle Scholar
  58. Miltner FO (1982) Wertigkeit der symptomatischen Therapie mit Memantin beim zerebralen Koma. I. Korrelation von Komastadien und EEG-Spektralverläufen. Arzneimittelforschung/Drug Res 32: 1268–1270Google Scholar
  59. Mistry R, Wilke R, Challiss RAJ (1995) Modulation of NMDA effects on agonist-stimulated phophoinositide turnover by memantine in neonatal rat cerebral cortex. Br J Pharmacol 114: 797–804PubMedCrossRefGoogle Scholar
  60. Misztal M, Frankiewicz T, Parsons CG, Danysz W (1996) Learning deficits induced by chronic intraventricular infusion of quinolinic acidprotection by MK-801 and memantine. Eur J Pharmacol 296: 1–8PubMedCrossRefGoogle Scholar
  61. Mundinger F, Milios E (1985) Erfahrungen mit Memantine bei der Behandlung schwerer spastischer und extrapyramidaler Bewegungsstörungen in Kombination mit der stereotaktischen Operation. Nervenarzt 56: 106–109PubMedGoogle Scholar
  62. Müller WEG, Schröder HC, Ushijima H, Dapper J, Bormann J (1992) gpl20 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by memantine. Eur J Pharmacol 226: 209–214PubMedCrossRefGoogle Scholar
  63. Olney JW, Labruyere J, Price MT (1989) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360–1362PubMedCrossRefGoogle Scholar
  64. Osborne NN, Quack G (1992) Memantine stimulates inositol phosphates production in neurones and nullifies N-methyl-D-aspartate-induced destruction of retinal neurones. Neurochem Int 21: 329–336PubMedCrossRefGoogle Scholar
  65. Pantev M, Ritter R, Görtelmeyer R (1993) Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Z Gerontopsychol 6: 103–117Google Scholar
  66. Parsons CG, Grüner R, Rozental J, Millar J, Lodge D (1993) Patch clamp studies on the kinetic and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32: 1337–1350PubMedCrossRefGoogle Scholar
  67. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34: 1239–1258PubMedCrossRefGoogle Scholar
  68. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA (1996) Comparative patch clamp studies with freshly dissociated rat hippocampal and striatal neurones on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 8: 446–454PubMedCrossRefGoogle Scholar
  69. Petersen RC, Stillman RC (1978) Phencyclidine: an overview. In: Petersen RC, Stillman RC (eds) NIDA research monograph, pp 1–17Google Scholar
  70. Quack G, Hesselink M, Danysz W, Spanagel R (1995) Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J Neural Transm [Suppl] 46: 97–105Google Scholar
  71. Rabey JM, Nissipeanu P, Korczyn AD (1992) Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson’s disease. J Neural Transm [PD-Sect] 4: 277–282CrossRefGoogle Scholar
  72. Reiser G, Koch R (1989) Memantine inhibits serotonin-induced rise of cytosolic Ca2+ activity and of cytosolic GMP level in a neuronal cell fine. Eur J Pharmacol Mol Pharmacol Sect 172: 199–203CrossRefGoogle Scholar
  73. Reiser G, Binmöller F-J, Koch R (1988) Memantine (1-amino-3,5-dimethyladamantane) blocks the serotonin-induced depolarization response in a neuronal cell line. Brain Res 443: 338–344PubMedCrossRefGoogle Scholar
  74. Riederer P, Lange KW, Kornhuber J, Danielczyk W (1991) Pharmacotoxic psychosis after memantine in Parkinson’s disease. Lancet 338: 1022–1023PubMedCrossRefGoogle Scholar
  75. Rieke J, Glaser A (1996) Wirksamkeit und Verträglichkeit von Memantine bei Patienten mit dementiellem Syndrom. Med Welt 47: 251–254Google Scholar
  76. Rüther E, Glaser A (1998) The NMDA-antagonist memantine in severe dementia. 6th International Conference on Alzheimer Disease and Related Disorders, AmsterdamGoogle Scholar
  77. Schäfer E, Thiery I (1984) Geriatrie: zerebrale Leistungssteigerung durch Memantine. Psycho 1–8Google Scholar
  78. Schneider E, Fischer P-A, Clemens R, Balzereit F, Fünfgeld EW, Haase H-J (1984) Wirkungen oraler Memantin-Gaben auf die Parkinson-Symptomatik. Dtsch Med Wochenschr 109: 987–990PubMedCrossRefGoogle Scholar
  79. Schugens MM, Egerter R, Daum I, Schepelmann K, Klockgether T, Löschmann PA (1997) The NMDA antagonist memantine impairs classical eyeblink conditioning in humans. Neurosci Lett 224: 57–60PubMedCrossRefGoogle Scholar
  80. Seif EL Nasr M, Peruche B, Rossberg C, Mennel H-D, Kriegelstein J (1990) Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 185: 19–24CrossRefGoogle Scholar
  81. Sharp FR, Jasper P, Hall J, Noble L, Sagar SM (1991) MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann Neurol 30: 801–809PubMedCrossRefGoogle Scholar
  82. Sontag K-H, Wand P, Schwarz M, Wesemann W, Osborne NN (1982) Die Wirkung von Memantine auf spinale α-Motoneurone und auf Gehalt von Dopamin, Noradrenalin und Serotonin des Striatums und lumbalen Rückenmarks. Arzneimittelforschung/Drug Res 32: 1236–1240Google Scholar
  83. Spanagel R, Kornhuber J (1999) Glutamatrezeptorantagonisten und Alkoholabhängigkeit. Präklinische Befunde. Nervenarzt 70:479–481PubMedCrossRefGoogle Scholar
  84. Spanagel R, Eilbacher B, Wilke R (1994) Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat — a pharmacokinetic microdialysis study. Eur J Pharmacol 262: 21–26PubMedCrossRefGoogle Scholar
  85. Stelzer G (1984) Einfluβ von Memantine bei Kurz-, Mittel-und Langzeitgabe auf die Werte des klinisch-chemischen Labors. Med Welt 34: 291–295Google Scholar
  86. Stieg PE, Sathi S, Alvarado SP, Jackson PS, Pelligrini JW, Chen H-SV, Lipton SA, Jensen FE (1993) Post-stroke neuroprotection by memantine minimally affects behavior and does not block LTP. Soc Neurosci Abstr 19: 1503Google Scholar
  87. Szatkowski M, Attwell D (1994) Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci 17: 359–365PubMedCrossRefGoogle Scholar
  88. Teitelbaum JS, Zatorre RJ, Carpenter S, Gendron D, Evans AC, Gjedde A, Cashman NR (1990) Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 322: 1781–1787PubMedCrossRefGoogle Scholar
  89. Tomitaka S, Hashimoto K, Narita N, Sakamoto A, Minabe Y, Tamura A (1996) Memantine induces heat shock protein HSP70 in the posterior cingulate cortex, retrosplenial cortex and dentate gyrus of rat brain. Brain Res 740: 1–5PubMedCrossRefGoogle Scholar
  90. Tsai M-C, Chen M-L, Lo S-C, Tsai G-C (1989) Effects of memantine on the twitch tension of mouse diaphragm. Eur J Pharmacol 160: 133–140PubMedCrossRefGoogle Scholar
  91. Verspohl EJ, Koch R, Schatton W (1988) Interaction of memantine with cholecystokinin receptors in mouse brain. J Pharm Pharmacol 111–115Google Scholar
  92. Weller M, Finiels-Marlier F, Paul SM (1993) NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 613: 143–148PubMedCrossRefGoogle Scholar
  93. Wenk GL, Danysz W, Mobley SL (1995) MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 293: 267–270PubMedCrossRefGoogle Scholar
  94. Wenk GL, Danysz W, Roice DD (1996) The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. NeuroReport 7: 1453–1456PubMedCrossRefGoogle Scholar
  95. Wenk GL, Zajaczkowski W, Danysz W (1997) Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res 83: 129–133PubMedCrossRefGoogle Scholar
  96. Wesemann W, Ekenna O (1982) Effect of 1-amino-adamantanes on the MAO activity in brain, liver, and kidney of the rat. Arzneimittelforschung/Drug Res 32: 1241–1243Google Scholar
  97. Wesemann W, Schollmeyer JD, Sturm G (1977) Gaschromatographische und massenspektrometische Untersuchungen über harnpflichtige Metabolite von Adamantanaminen. Arzneimittelforschung/Drug Res 27: 1471–1477Google Scholar
  98. Wesemann W, Dette-Wildenhahn G, Fellehner H (1979) In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson. J Neural Transm 44: 263–285PubMedCrossRefGoogle Scholar
  99. Wesemann W, Sturm G, Fünfgeld EW (1980) Distribution and metabolism of the potential antiparkinson drug memantine in the human. J Neural Transm [Suppl] 16: 143–146Google Scholar
  100. Wesemann W, Sontag K-H, Maj J (1983) Zur Pharmakodynamik und Pharmakokinetik des Memantin. Arzneimittelforschung/Drug Res 33: 1122–1134Google Scholar
  101. Winblad B, Poritis N (1999) Memantine in severe dementia: results of the M-9-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14: 135–146PubMedCrossRefGoogle Scholar
  102. Zajaczkowski W, Quack G, Danysz W (1996) Infusion of (+)-MK-801 and memantine — contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 296: 239–246PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • J. Kornhuber
  • S. Bleich

There are no affiliations available

Personalised recommendations